Orion Corporation: Managers’ transactions – Niclas Lindstedt

ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET

Orion Corporation: Managers’ transactions – Niclas Lindstedt

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

---

Person subject to the notification requirement Name: Niclas Lindstedt Position: Other senior manager Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 146386/7/6

---

Transaction date: 2026-03-10 Outside a trading venue Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details (1): Volume: 5003 Unit price: 0 EUR

Aggregated transactions (1): Volume: 5003 Volume weighted average price: 0 EUR

Orion Corporation

Liisa Hurme President and CEO

Mikko Kemppainen General Counsel

Publisher:

Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland http://www.orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.